Inmune Bio, Inc. current report, 27 October 2021

Vollständiges Dokument

Business Context and Reporting Period

Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 27, 2021
Reporting Period: Event date October 27, 2021
Business Context: The Company is a Nevada corporation focused on developing therapies for Alzheimer's Disease (AD). This filing announces upcoming scientific presentations at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting.

Financial Metrics

This filing is an "Other Events" report (Item 8.01) and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.

Material Changes

No material financial changes or operational changes versus a prior comparable period are reported in this document. The filing solely discloses the scheduling of scientific presentations.

Outlook, Management Commentary, and Risks

Upcoming Events: The Company announced multiple poster presentations and a plenary talk scheduled for the CTAD Annual Meeting (November 9-12, 2021, in Boston).
Key Presentations:

  • Late-breaking oral presentation: "The Early Mild Alzheimer's Cognitive Composite (EMACC): a meaningful primary cognitive endpoint in a phase 2 trial of XPro1595 in Alzheimer's Disease (AD) with inflammation (ADi)" by Dr. Judith Jaeger.
  • Late-breaking oral communication: "Analyzing the CSF proteome to support decisions in an AD clinical trial program."
  • Poster presentations: Topics include novel white matter imaging measures, MRI measures replacing CSF sampling, and a three-step process for defining Phase II trial size using patient enrichment strategies.
Risks and Contingencies: No specific risks or contingencies are detailed in this filing beyond the standard nature of clinical trial data presentation.

Key Facts for Investor Verification

  • Verify the dates and format (hybrid/in-person/virtual) of the CTAD Annual Meeting presentations.
  • Confirm the specific findings or data to be presented regarding the XPro1595 Phase 2 trial and EMACC endpoint.
  • Review the attached Exhibit 99.1 (Press Release) for full details on the scientific content.
  • Note that this filing contains no financial performance data; refer to recent 10-Q or 10-K filings for financial status.